Current first-line therapy for stage IV melanoma generally includes either a checkpoint inhibitor or a BRAF/MEK tyrosine kinase inhibitor combination for patient’s bearing tumors that carry a V600E or V600K BRAF mutation. The gene discussed is BRAF; the disease is melanoma.